ReWalk Robotics’ (LFWD) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of ReWalk Robotics (NASDAQ:LFWD) in a report released on Wednesday morning,Benzinga reports. They currently have a $13.00 price objective on the stock.

ReWalk Robotics Trading Down 7.2 %

Shares of LFWD opened at $1.80 on Wednesday. The firm’s 50 day moving average is $2.74 and its 200-day moving average is $3.66. The stock has a market capitalization of $15.86 million, a PE ratio of -0.72 and a beta of 2.07. ReWalk Robotics has a 12 month low of $1.80 and a 12 month high of $9.10.

ReWalk Robotics (NASDAQ:LFWD) last announced its quarterly earnings results on Thursday, August 15th. The company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.03. ReWalk Robotics had a negative return on equity of 43.02% and a negative net margin of 77.21%. The business had revenue of $6.71 million for the quarter, compared to analyst estimates of $6.71 million. During the same quarter in the prior year, the company earned ($0.35) earnings per share. Equities research analysts predict that ReWalk Robotics will post -1.65 earnings per share for the current fiscal year.

Institutional Trading of ReWalk Robotics

A hedge fund recently bought a new stake in ReWalk Robotics stock. Dimensional Fund Advisors LP acquired a new stake in shares of ReWalk Robotics Ltd. (NASDAQ:LFWD) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 13,548 shares of the company’s stock, valued at approximately $54,000. Dimensional Fund Advisors LP owned about 0.16% of ReWalk Robotics at the end of the most recent reporting period. 26.76% of the stock is owned by institutional investors.

About ReWalk Robotics

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke.